Vandetanib by STEMCELL Technologies Inc.

Manufacturer STEMCELL Technologies Inc.  |   Model: 73532
Tyrosine kinase inhibitor; Inhibits VEGFR1, KDR, FLT-4, EGFR, FGFR, ABL, RET, and SRC


Vandetanib by STEMCELL Technologies Inc. product image
Vandetanib

The supplier does not provide quotations for this particular product through SelectScience. You can search for similar products in our product directory.



0 Scientists have reviewed this product


Write the First Review

No Reviews

Vandetanib is a multi-kinase inhibitor targeting primarily receptor tyrosine kinases, such as vascular endothelial growth factor receptors (VEGFR1, KDR, and FLT4), epidermal growth factor receptor (EGFR), and fibroblast growth factor receptor (FGFR; Morabito et al.). It most potently inhibits KDR with an IC₅₀ of 40 nM. It also inhibits non-receptor tyrosine kinases such as RET, ABL, and SRC as well as several serine/threonine kinases (Carlomagno et al.; Hennequin et al.; Kiselyov et al.; Levinson & Boxer).

CANCER RESEARCH

  • Inhibits tumor growth in mouse xenograft models, including RET/PTC papillary thyroid carcinoma and lung carcinoma (Hennequin et al.; Carlomagno et al.).
  • Inhibits angiogenesis, cell growth, and metastasis in numerous cancer cell lines (Morabito et al.; Wedge et al.).